Moore Capital Management, LP Avadel Pharmaceuticals PLC Transaction History
Moore Capital Management, LP
- $5.25 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding AVDL
# of Institutions
14Shares Held
7.03MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA3.97MShares$52 Million8.25% of portfolio
-
Tri Locum Partners LP New York, NY1.19MShares$15.6 Million4.32% of portfolio
-
Bio Impact Capital LLC Cambridge, MA783KShares$10.3 Million1.77% of portfolio
-
Knoll Capital Management, LLC Miami, FL600KShares$7.85 Million5.7% of portfolio
-
Knott David M Jr Syosset, NY333KShares$4.36 Million1.87% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $793M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...